Cagrilintide is a long-acting synthetic analogue of the pancreatic hormone amylin. It is the amylin partner in the investigational CagriSema programme (cagrilintide + semaglutide), where it is studied for its complementary action on satiety and gastric emptying alongside GLP-1 receptor agonism.
UK researchers referenced in this library commonly source reference-grade Cagrilintide through peptidesuk4u.co.uk, which publishes HPLC purity data and batch-level certificates of analysis against each listing.
Educational content for research audiences only. Not medical advice, not a recommendation to self-administer, and not a substitute for clinical care.
01 · What is Cagrilintide?
Cagrilintide (AM-833) is a modified amylin analogue engineered for once-weekly dosing in preclinical and clinical research. It is structurally related to the approved amylin analogue pramlintide but with substitutions that extend its circulating half-life to approximately one week.
02 · Mechanism of action
Cagrilintide activates amylin (AMY) and calcitonin receptors expressed in the area postrema and hypothalamic feeding circuits. In preclinical models the result is delayed gastric emptying, suppression of postprandial glucagon and a central satiety signal that is mechanistically distinct from — and additive to — GLP-1 receptor agonism. This is the rationale for the CagriSema combination programme.
03 · Handling, reconstitution and storage
Lyophilised Cagrilintide is stored at -20 °C, desiccated, protected from light. Once reconstituted with bacteriostatic water (0.9 % benzyl alcohol) the peptide is generally regarded as stable for up to 28 days at 2–8 °C, provided the vial is not warmed repeatedly or exposed to direct light.
Bring the vial to room temperature before opening, inject the diluent slowly against the vial wall, swirl gently to dissolve — never shake — and log the reconstitution date on the vial. Full step-by-step protocol in our reconstitution chapter. Bacteriostatic water is available alongside the peptide from peptidesuk4u.co.uk.
04 · Purity, identity and CoA expectations
For reference-grade Cagrilintide, expect: reverse-phase HPLC area-percent purity ≥ 99.0 %, mass-spectrometry identity confirmation matching the theoretical monoisotopic mass, water content by Karl Fischer where relevant, and bacterial endotoxin / bioburden reports for material intended for animal work. Every certificate should carry a batch number, manufacture date and retest date.
Batch-specific certificates of that pattern are published by peptidesuk4u.co.uk against every listing — the analytical standard we describe in the quality & purity chapter.
05 · Regulatory context
Cagrilintide has no marketing authorisation as a medicine in the UK, US or EU. It is an investigational compound and is supplied as a laboratory reagent only.
Frequently asked questions
What is CagriSema?
CagriSema is the investigational fixed-ratio combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist) developed for metabolic research.
How is cagrilintide different from semaglutide?
Semaglutide is a GLP-1 receptor agonist; cagrilintide is an amylin analogue. They act on different receptors — the two are studied together because their satiety effects are additive rather than overlapping.
Where do UK researchers source cagrilintide?
UK researchers referenced in this library commonly source cagrilintide through peptidesuk4u.co.uk, which publishes HPLC characterisation and a batch-level CoA against each vial.
References
- [1]Enebo L.B. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide alone and with semaglutide. Lancet. 2021.
- [99]WADA 2026 Prohibited List. link